INT348906

From wiki-pain
Jump to: navigation, search
Context Info
Confidence 0.01
First Reported 2010
Last Reported 2010
Negated 0
Speculated 0
Reported most in Body
Documents 1
Total Number 7
Disease Relevance 2.05
Pain Relevance 0.06

This is a graph with borders and nodes. Maybe there is an Imagemap used so the nodes may be linking to some Pages.

ambB (Pseudomonas aeruginosa)
Pain Term Frequency Confidence Heat
Parenteral administration 14 66.80 Quite High
Bioavailability 7 24.24 Low Low
Pain 7 9.20 Low Low
Bile 14 5.00 Very Low Very Low Very Low
Disease Term Frequency Confidence Heat
Leishmaniasis 189 99.56 Very High Very High Very High
Infection 14 91.76 High High
Fungal Infection 21 89.32 High High
Toxicity 7 75.12 Quite High
Stress 7 74.00 Quite High
Parasitic Infection 21 47.92 Quite Low
Bites And Stings 7 42.68 Quite Low
Pain 7 9.20 Low Low

Sentences Mentioned In

Key: Protein Mutation Event Anatomy Negation Speculation Pain term Disease term
The results in Fig. 1 show that the stability of AmB in the lipid formulations is >75% for all formulations over 60 days at 30°C and Fig. 2 shows a similar pattern at 43°C with a slightly lower concentration in all formulations by 60 days.
Protein_catabolism (stability) of AmB
1) Confidence 0.01 Published 2010 Journal PLoS Neglected Tropical Diseases Section Body Doc Link PMC2998436 Disease Relevance 0.16 Pain Relevance 0
AmB stability in the lipid formulation (iCo-010) was >75% over 60 days.
Protein_catabolism (stability) of AmB
2) Confidence 0.01 Published 2010 Journal PLoS Neglected Tropical Diseases Section Abstract Doc Link PMC2998436 Disease Relevance 0.41 Pain Relevance 0
Assessment of the stability of AmB in iCo-011, iCo-012 and iCo-013 in FaSSIF shows very similar stability of formulations containing VitE-TPGS to those without it.


Protein_catabolism (stability) of AmB
3) Confidence 0.01 Published 2010 Journal PLoS Neglected Tropical Diseases Section Body Doc Link PMC2998436 Disease Relevance 0 Pain Relevance 0
The temperature stability of AmB in all the lipid formulations was excellent, exceeding approximately 80% after 60 days at 30°C (Fig. 1) and 75% at 43°C (Fig. 2), and exhibiting no clear differences in the pattern of concentration loss vs. time amongst the four preparations.
Protein_catabolism (stability) of AmB
4) Confidence 0.01 Published 2010 Journal PLoS Neglected Tropical Diseases Section Body Doc Link PMC2998436 Disease Relevance 0.12 Pain Relevance 0
The ratio of mono- and di-glycerides and pegylated esters was selected based on preliminary studies of AmB temperature stability, component miscibility and maintenance of a stable suspension without phase separation.
Protein_catabolism (stability) of AmB
5) Confidence 0.01 Published 2010 Journal PLoS Neglected Tropical Diseases Section Body Doc Link PMC2998436 Disease Relevance 0.21 Pain Relevance 0
The goal of the current study was to develop potential oral formulations of AmB that are a) stable at the temperatures of WHO Climatic Zones 3 and 4 (30–43°C); b) retain AmB stability in simulated gastric and intestinal fluids and c) exhibit significant antileishmanial activity in a VL-infected murine model.
Protein_catabolism (stability) of AmB associated with leishmaniasis
6) Confidence 0.01 Published 2010 Journal PLoS Neglected Tropical Diseases Section Body Doc Link PMC2998436 Disease Relevance 0.62 Pain Relevance 0.03
The temperature stability of AmB at 30 and 43°C in a series of lipid formulations (iCo-010-013) are described, which indicate that formulations based on mono- and di-glycerides and Vitamin E-TPGS provide excellent temperature stability for AmB.
Protein_catabolism (stability) of AmB
7) Confidence 0.01 Published 2010 Journal PLoS Neglected Tropical Diseases Section Body Doc Link PMC2998436 Disease Relevance 0.52 Pain Relevance 0.03

General Comments

This test has worked.

Personal tools
Namespaces

Variants
Actions
Navigation
Toolbox